Ottobock, one of the world’s most influential prosthetics and orthotics companies, has rejected allegations made in a new short-seller report by Grizzly Research, after the report raised questions about the company’s shareholder structure, Russia exposure, accounting treatment and valuation.
The report, published by Grizzly Research on 19 May 2026, alleges that Ottobock faces risks linked to majority shareholder Hans Georg Näder’s financing arrangements, the company’s continuing Russia business, and what Grizzly describes as aggressive accounting practices. Grizzly also states that it is short Ottobock shares and therefore has an economic interest in a falling share price. Ottobock has strongly rejected the report, calling it misleading and stating that it is reviewing legal steps, including possible notification to German supervisory authorities. (Grizzly Research) (Ottobock statement)
For the orthotics and prosthetics sector, the dispute matters because Ottobock is not simply a listed medtech company. It is a central supplier of prosthetic knees, feet, orthoses, bionic systems, clinical services and mobility technologies used by clinicians and patients worldwide. Any market debate around its governance, financial reporting or regional exposure is therefore relevant to O&P providers, distributors, investors and health systems across the IMEA region.
Grizzly’s report makes several major claims. It alleges that Näder has pledged his Ottobock shares as part of a margin loan structure, while retaining control through a holding arrangement. It also claims that the company’s Russia business is more important to profitability than publicly appreciated, and questions Ottobock’s use of underlying or adjusted performance metrics. Grizzly further argues that Ottobock’s stock is overvalued relative to what it sees as the company’s underlying growth and risk profile. (Grizzly Research)
Ottobock responded on 20 May 2026, stating that it “categorically rejects” the report and the conclusions drawn from it. The company said Grizzly did not contact Ottobock before publication and described the report as a short-biased opinion by a party that has disclosed a financial interest in a lower share price. Ottobock said the issues raised either had already been disclosed, had previously been reported and proven false, or concerned private matters at shareholder level. (Ottobock statement)
On accounting, Ottobock said its financial reporting is prepared under IFRS and audited by independent auditor KPMG AG Wirtschaftsprüfungsgesellschaft. It stated that development cost capitalisation follows IAS 38, while depreciation periods for property, plant and equipment are based on expected useful economic life under IAS 16. The company also defended its presentation of “Core” and “Non-Core” business figures, saying the separation increases transparency during portfolio streamlining. (Ottobock statement)
On Russia, Ottobock rejected Grizzly’s calculation of Russia’s contribution to net income and said the report used false metrics. The company stated that in Russia it focuses exclusively on supplying civilians, has no contracts with the military or military-related institutions, and does not participate in military tenders. (Ottobock statement)
The debate follows Ottobock’s stock-market listing in Frankfurt in October 2025. Reuters reported that the IPO valued the company at around €4.2 billion, with shares priced at €66 and opening at €72. Ottobock received approximately €100 million from the offering, while most proceeds went to the founding Näder family, which retained more than 80% of the shares at listing. Reuters also noted at the time that the family still owed financiers around €1 billion, with repayment due by the first quarter of 2030. (Reuters)
Ottobock’s published 2025 results showed strong reported growth. The company said core revenues rose 11.7% to €1.6 billion, underlying core EBITDA increased 29.5% to €415.3 million, and underlying net income rose 83.2% to €177.3 million. Ottobock also reported that its EMEA segment remained its largest by revenue, supported by products including the Genium X4 microprocessor knee and the Taleo prosthetic foot portfolio. (Ottobock 2025 annual report announcement)
For clinicians and distributors in the IMEA region, the immediate operational impact of the dispute may be limited. The report is primarily a capital-markets challenge rather than a product safety or clinical performance claim. However, the controversy does raise broader questions that matter for the O&P sector, particularly around transparency, supply-chain resilience, regional exposure and the responsibilities of global assistive-technology companies operating in politically sensitive markets.
Ottobock’s global role is substantial. The company supplies major prosthetic and orthotic technologies used in advanced clinical services, including microprocessor knees, prosthetic feet, upper-limb systems, orthoses and patient-care networks. Its influence extends into training, reimbursement discussions, digital workflows and standards of care. As a result, investor controversies involving Ottobock can affect confidence not only in the company’s shares, but also in the broader perception of O&P as an investable medtech sector.
This is especially relevant as prosthetics and orthotics attract increasing attention from public markets, private equity, family offices and strategic investors. O&P has historically been a specialist clinical and technical field, but it is now increasingly shaped by consolidation, patient-care acquisitions, digital manufacturing, bionic technology, robotics, exoskeletons and public-market scrutiny. The Ottobock case shows that major O&P companies are now being judged not only by clinical reputation, but also by governance standards, reporting transparency and geopolitical risk.
For IMEA CPO readers, several points are worth watching:
It is also important to treat the Grizzly report appropriately. It is not an independent regulatory finding or court judgment. It is a short-seller report containing allegations and opinions by a party that has disclosed a short position. At the same time, such reports can influence market behaviour and may prompt companies to provide additional explanations. Ottobock has rejected the allegations and reaffirmed the integrity of its audited financial statements, securities prospectus and capital-market disclosures. (Grizzly Research) (Ottobock statement)
For the rehabilitation sector, the broader lesson is that leading assistive-technology companies are no longer operating only in clinical markets. They are also operating in public financial markets where governance, disclosure and geopolitical exposure can quickly become central issues. As the O&P industry matures, transparency will become increasingly important to investors, clinicians, distributors and patients alike.
Ottobock remains one of the most important companies in global prosthetics and orthotics. The current dispute does not change its clinical footprint, product portfolio or historical role in the sector. But it does underline a new reality: as O&P companies grow, list and consolidate, their financial structures and governance practices will be watched more closely by the market — and by the healthcare professionals who depend on them.